Yuhan Corp Preferred (000105) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Yuhan Corp Preferred (000105) has a cash flow conversion efficiency ratio of 0.003x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩7.70 Billion ≈ $5.22 Million USD) by net assets (₩2.36 Trillion ≈ $1.60 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 000105 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Yuhan Corp Preferred - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Yuhan Corp Preferred's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Yuhan Corp Preferred Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Yuhan Corp Preferred ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pacific Pipe Public Company Limited
BK:PAP
|
0.056x |
|
Franklin Street Properties Corp
NYSE MKT:FSP
|
-0.009x |
|
Star Media Group Bhd
KLSE:6084
|
-0.014x |
|
Orient Ceratech Limited
NSE:ORIENTCER
|
0.100x |
|
Mink Therapeutics Inc
NASDAQ:INKT
|
0.070x |
|
Sirios Resources Inc.
V:SOI
|
-0.045x |
|
GeneOne Life Science Inc
KO:011000
|
-0.043x |
|
Senstar Technologies Ltd
NASDAQ:SNT
|
0.009x |
Annual Cash Flow Conversion Efficiency for Yuhan Corp Preferred (2014–2025)
The table below shows the annual cash flow conversion efficiency of Yuhan Corp Preferred from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Yuhan Corp Preferred stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩2.36 Trillion ≈ $1.60 Billion |
₩106.23 Billion ≈ $71.99 Million |
0.045x | +77.12% |
| 2024-12-31 | ₩2.15 Trillion ≈ $1.46 Billion |
₩54.60 Billion ≈ $37.00 Million |
0.025x | -60.58% |
| 2023-12-31 | ₩1.98 Trillion ≈ $1.34 Billion |
₩127.75 Billion ≈ $86.58 Million |
0.064x | +29.92% |
| 2022-12-31 | ₩2.01 Trillion ≈ $1.36 Billion |
₩99.53 Billion ≈ $67.45 Million |
0.050x | -3.07% |
| 2021-12-31 | ₩1.94 Trillion ≈ $1.31 Billion |
₩99.00 Billion ≈ $67.09 Million |
0.051x | +227.54% |
| 2020-12-31 | ₩1.85 Trillion ≈ $1.25 Billion |
₩28.83 Billion ≈ $19.54 Million |
0.016x | -60.96% |
| 2019-12-31 | ₩1.65 Trillion ≈ $1.12 Billion |
₩65.99 Billion ≈ $44.72 Million |
0.040x | -29.32% |
| 2018-12-31 | ₩1.65 Trillion ≈ $1.12 Billion |
₩93.45 Billion ≈ $63.33 Million |
0.057x | -27.94% |
| 2017-12-31 | ₩1.61 Trillion ≈ $1.09 Billion |
₩126.13 Billion ≈ $85.47 Million |
0.079x | +58.48% |
| 2016-12-31 | ₩1.50 Trillion ≈ $1.01 Billion |
₩74.14 Billion ≈ $50.25 Million |
0.050x | -46.47% |
| 2015-12-31 | ₩1.36 Trillion ≈ $924.32 Million |
₩126.23 Billion ≈ $85.55 Million |
0.093x | +25.11% |
| 2014-12-31 | ₩1.28 Trillion ≈ $864.64 Million |
₩94.39 Billion ≈ $63.96 Million |
0.074x | -- |
About Yuhan Corp Preferred
Yuhan Corporation operates as a pharmaceutical company in South Korea and internationally. It offers manufacturing services, such as custom manufacturing; process research and development of active pharmaceutical products (APIs) and intermediates; kilo and pilot-scale production of APIs and intermediates; commercial production of APIs and intermediates; production of chemical specialties; and ana… Read more